arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Entera Bio Ltd.

ENTX
$2.87 ▲ +0.04 (+1.23%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
25 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

Entera Bio Ltd. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $137.1M
Dividend Yield
Revenue Growth N/M
Op. Margin
ROIC -26.2%
FCF / Share $-0.06
Trailing P/E 41.0x
Price / Book 12.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

25-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-3.50M
↓ -36.5%
FCF / Share Free cash flow per share
$-0.06
↓ -98.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
10
Cash Quality
46

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 25 quarters